Connect with us

Hi, what are you looking for?

Life

Migraine Tool Reduces Suffering

A migraine treatment breakthrough will be discussed today at the
American Academy of Neurology annual meeting. Results of an
international trial sponsored by AstraZeneca (NYSE:AZN) show that MIDAS,
an innovative, yet simple, five-question form, helps migraine patients
find appropriate medication the first time they talk to their doctor.
Without this tool, many patients suffer through a lengthy and
inefficient treatment process starting with simple analgesics and
working their way up to more potent medications when previous
medications fail.

The MIDAS questionnaire, for Migraine Disability Assessment Scale, is
designed to allow patients with severe migraine to skip simple
analgesics in the course of treatment. In the past, physicians have not
had a clinically relevant reliable tool to assess disability at the
onset of treatment, so they have started patients with a simple
analgesic, regardless of the severity of their migraine attacks.

Doctors use MIDAS to measure a sufferer’s disability and assign a score
based on answers to questions about time lost from the workplace,
housework and leisure activities. This information helps physicians to
select the most appropriate treatment plan, giving simple analgesics
like aspirin to patients with lower scores and prescribing more powerful
medications to patients with higher scores.

www.astrazeneca-us.com
www.zomig.com.

You may also like:

Life

US troops are found in almost every country on the planet, with some places having a greater concentration of soldiers than others.

Business

Image courtesy of Terri DavisTerri is a thought leader in Digital Journal’s Insight Forum (become a member). “So, the biggest long‑term danger is that,...

Life

Katy Johnson chatted about being a travel blogger, realtor, and fashion model in the digital age.

Social Media

Linda Yaccarino resigned as CEO of X, the social media platform formerly known as Twitter, after two years at the helm of the Musk-owned...